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ABSTRACT Ras proteins are small GTP binding proteins
that serve as critical relays in a variety of signal transduction
pathways in eukaryotic cells. Like most metazoan Ras pro-
teins, yeast Ras is post-translationally modified by addition of
a farnesyl and a palmitoyl moiety, and these modifications are
required for targeting the protein to the cytoplasmic face of
the plasma membrane and for biological activity of the
protein. We have constructed mutants of the yeast (Saccha-
romyces cerevisiae) Ras that are farnesylated in vivo but are not
palmitoylated. These mutant proteins are not localized to the
plasma membrane but function in the cell as well as the
wild-type protein. Such mutants are viable but fail to induce
a transient increase in intracellular cAMP concentration in
response to glucose addition, although this deficiency does not
yield a marked growth phenotype. These results are consistent
with the hypothesis that the essential role of the farnesyl
moiety on yeast Ras is to enhance productive interaction
between Ras and its essential downstream target, adenylyl
cyclase, rather than to localize Ras to the plasma membrane.
All Ras proteins undergo a series of post-translational mod-
ifications of their carboxyl termini, including farnesylation and
in most cases palmitoylation, that are required for partitioning
the proteins to the cytoplasmic face of the plasma membrane
(1-10). In metazoans, this localization appears to be essential
for Ras's role in signal transduction, since signaling through
the pathway relies on repartitioning the Ras activating protein,
Sos, and the Ras effector protein, Raf, to the membrane
compartment at which Ras resides as the means of completing
the signaling circuit (11-17).
Yeast Ras proteins participate in a signal transduction
pathway that appears to connect glucose availability to the
metabolic activity of the cell. The two Ras proteins, encoded
by RASI and RAS2, stimulate adenylyl cyclase to yield in-
creased cAMP levels, which in turn activates the cAMP-
dependent protein kinase (A kinase) (18, 19). Phosphorylation
of a number of target proteins by activated A kinase results in
enhanced glycolysis, mobilization of energy reserves, and
specific transcriptional activation. The precise biological signal
that activates Ras is not known, but addition of glucose to
starved cells yields a transient increase in cAMP levels that is
dependent on Ras and on the Ras guanine nucleotide ex-
change factor, Cdc25p (20-24).
Previous observations have established a correlation be-
tween post-translational processing of Ras, its membrane
localization, and its biological activity. Like metazoan Ras
proteins, yeast Ras proteins are post-translationally modified
by farnesylation, palmitoylation, proteolytic removal of the
terminal three amino acids, and carboxyl methylesterification
(2, 6, 9). Yeast Ras proteins are located predominantly in the
cell in a membrane compartment, as are other components of
the signal transduction pathway with which Ras interacts,
including adenylyl cyclase and Cdc25p (M. Jacquet, personal
communication; refs. 25 and 26). Mutation of the site of
farnesylation in Ras blocks all post-translational processing,
abolishes its biological activity, and renders the protein pre-
dominantly cytoplasmic (27). This has prompted models sug-
gesting that post-translational modification of Ras is essential
for its biological activity because it allows colocalization of Ras
with other components of the signal transduction apparatus.
In this report we describe mutants of Ras in Saccharomyces
cerevisiae that separate membrane localization from biological
activity. We have found that mutations of the palmitoylation
site of Ras block palmitoylation but not other post-trans-
lational processing steps. In contrast to wild-type Ras protein,
these mutant proteins are not localized to the plasma mem-
brane and do not support a glucose-mediated transient induc-
tion of cAMP. However, these mutant proteins perform their
essential function in the cell as well as the wild-type protein.
Thus, these results clearly separate membrane localization and
glucose signaling from the essential role of Ras in yeast and
support the hypothesis that the primary role of post-
translational modification of Ras is in direct protein-protein
interaction.
MATERIALS AND METHODS
Plasmids and Strains. Strain KP-2 (MATa trpl-289 leu2-3,
112 his3A ura3-52 ade8 canl ras2::URA3) was constructed by
transforming strain SP-1 (18) to Ura+ with pras2::URA3 (19).
Strain Y294 (MATa his3A1 leu2-3,112 ura3-52 trpl-289
GAL+), used for immunofluorescence, carried either the
wild-typeRAS2 or the mutant RAS2C3l8s or ras2C3l9s alleles on
plasmid YEpRAS2-1. Strain Y1810 (MATa/MATa leu2/leu2
his3/his3 ura3/ura3 trpl /trpl rasi :HIS3/rasl :HIS3
ras2C3l9s/RAS2::URA3) was obtained by crossing Y768 [des-
ignated SGP-4 in Deschenes and Broach (27)] with strain
Y1809 (MATa leu2 his3 ura3 trpl rasl:HKIS3 ras2C3l9s [pTLC1-
RAS2]) and then retrieving a diploid isolate that had lost the
pTLC1-RAS2 plasmid. Strain Y1809 was obtained as a seg-
regant from a cross between Y525 [designated RJS-1 in
Deschenes and Broach (27)] and Y651 (MATa his3 leu2 ura3
trpl ade8 rasl::HIS3 ras2::URA3 [pTLC1-RAS2]). Strain
Y1808 (MATa/MATa leu2/leu2 his3/his3 ura3/ura3 trpl/trpl
ade8/ade8 rasi :TRP1/rasl::HIS3 RAS2C3l8s/RAS2::URA3)
was obtained by crossing strain Y768 with a rasl::TRP1
RAS2C3l8s segregant from a cross between ST103 (MATa leu2
ura3 trpi leu2 ade8 rasl::TRP1 ras2::ADE8 [YEp24-RAS2])
and L1-D-1 (MATa ura3 trpl ku2 his3 RAS2C3l8s). Strains
1808-3A (RAS2+) and 1808-3C (RAS2c3lsS) were segregants
obtained by sporulating diploid Y1808. Isogenic derivatives of
strain RS62-22A (MA Ta his3 leu2 ura3 trpl ade2 ade8
ras2::URA3) containing the indicated RAS2 alleles were ob-
tained by a modified form of the counterselection method for
allele replacement (28) by cotransforming linear fragments
containing the RAS2 allele (29) along with plasmid pHV1 (30)
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selecting His' transformants and screening them for Ura-.
Allele replacement was confirmed by PCR analysis.
The 2 m,u plasmids YEp51 GAL10-RAS2 and YEp51
GAL10-RAS2C3l9s have been described (27). Plasmid YEp-
RAS2-1 (29) consists of the ADH1 promoter on a LEU2-2 m,u
vector and was used to express wild-type or mutant RAS2
alleles.
Growth Media. Yeast were grown either in rich medium
(YEPD: 1% yeast extract, 2% Bacto-Peptone, and 2% glucose)
or in synthetic medium [0.67% yeast nitrogen base without
amino acids, supplemented with the appropriate amino acid(s)
to satisfy auxotrophic requirements and the indicated carbon
source added to 2%].
Palmitate Labeling. Strains were grown to 107 cells per ml
in synthetic medium with raffinose (2%) as sole carbon source.
Synthesis of the wild-type or mutant Ras2p was induced by
addition of galactose to 2%, the cultures were split, and cells
in one half of each culture were labeled with [3H]palmitate.
Cells were harvested from all cultures after 2 hr and extracts
were prepared as described (31). For immunoblotting, 50-,tg
extracts from the unlabeled cultures were fractionated by SDS
gel electrophoresis, transferred to nitrocellulose, and probed
with anti-Ras antibody, Y13-259 (32). For autofluorography,
equal amounts of labeled extract (-5 x 107 total cpm) from
the two cultures were immunoprecipitated with Y13-259 an-
tibody. The precipitates were dissolved in sample buffer and
fractionated by SDS/PAGE, and the gel was subjected to
autofluorography for 3 weeks.
Immunofluorescence Analyses. Cells were grown to 107 cells
per ml in synthetic complete medium lacking leucine and then
fixed and prepared for immunofluorescence as described (33).
The primary anti-Ras2p monoclonal antibody, y-RAS2-3G6,
was used as undiluted culture supernatant; the goat anti-mouse
secondary antibody (Zymed) was conjugated with biotin and
visualized with fluorescein isothiocyanate-conjugated strepta-
vidin (Zymed) as described (34). Images were obtained with a
Bio-Rad MRC600 confocal imaging head, equipped with an
ILT argon/krypton laser, mounted on a Nikon Optiphot II
microscope using a 60X planapo objective (Nikon; numerical
aperture, 1.40; oil immersion objective; zoom factor, 2). While
optimal results for visualization of Ras protein localization
were obtained with strains in which Ras protein was moder-
ately overexpressed, identical results to those shown in Fig. 2
were obtained withRAS2 expressed under its own promoter on
an intermediate-copy level plasmid, pUV2, and on a low-copy
plasmid, pRS316. These constructs were also tested in a rasl
ras2 strain with identical results.
Iodine Assay and Heat Shock Analysis. Strains were grown
in YEPD plates and exposed to iodine vapors as described (18).
Heat shock analyses were performed by incubating YEPD
plates with the relevant strains at 55°C for the indicated times
and then shifting to 30°C for 24 hr (35).
RESULTS
Palmitoylation Is Required for Localization of Ras2p to the
Plasma Membrane. To evaluate the role of post-translational
modification of Ras in yeast, we introduced a series of
mutations into RAS2, the major Ras isoform in the cell, that
ablated different steps in the post-translational modification
program. We then evaluated the subcellular localization and
the biological activity of the resultant mutant proteins. Ras2p
is normally modified by a thioether linkage of farnesyl to
cysteine 319, a thioester linkage of palmitate to cysteine 318,
proteolytic removal of the carboxyl-terminal three amino
acids, and methyl esterification of the revealed carboxyl-
terminal cysteine 319. One mutation, C318S, prevented palmi-
toylation of the protein without affecting farnesylation, pro-
teolytic cleavage, or methyl esterification. A second mutation,
C319S, blocked farnesylation of the protein and, since farne-
sylation is required for all subsequent modifications, precluded
palmitoylation, cleavage, and methyl esterification as well (4).
The structures of the carboxyl termini of the wild-type Ras2p
and the two mutant proteins are summarized in Table 1. The
inability of Ras2p(C318S) to undergo palmitoylation is docu-
mented in Fig. 1. The absence of any modification of Ras-
2p(C319S) has been previously shown (27, 36, 37).
We examined the subcellular localization ofwild-type Ras2p
and the mutant Ras2p proteins by indirect immunofluores-
cence using confocal microscopy. As evident in Fig. 2, wild-
type Ras2p resides primarily on the plasma membrane. In
contrast, Ras2p(C318S), which lacks only the palmitoyl moi-
ety, and Ras2p(C319S), which lacks the palmitoyl and farnesyl
groups, are localized predominantly to the cytoplasm, with no
apparent enrichment in the plasma membrane. The patterns of
staining of the two mutant proteins are indistinguishable.
Identical results are obtained with strains carrying the RAS2
alleles on low-copy CENplasmids, indicating that <10% of the
Ras2p(C318S) is localized to the plasma membrane (data not
shown). Results from subcellular fractionation studies of the
wild-type and mutant proteins are consistent with those ob-
tained by immunofluorescence (data not shown). The require-
ment for membrane localization on palmitoylation is also
observed with two other mutant proteins, Ras2(A308-317)
and Ras2(A308-318). The former lacks the 10 amino acids
immediately upstream from the palmitoylation site and exhib-
its a wild-type localization pattern; in contrast, the latter
mutant lacks the same 10 amino acids as well as the palmi-
toylation site and shows no localization to the membrane (Fig.
2 Lower). Thus, membrane localization of Ras2p requires
palmitoylation in addition to farnesylation; farnesylation alone
is not sufficient to yield stable association of Ras2p with the
plasma membrane. Similar results are observed for mamma-
lian Ras proteins (38, 39).
Ras Biological Activity Requires Farnesylation But Not
Palmitoylation. Despite the fact that Ras2 protein lacking the
palmitoyl moiety alone and Ras2 protein lacking the palmitoyl
and farnesyl moieties show identical subcellular localization,
the biological activities of these two proteins are quite distinct.
The first demonstration of the difference in function of the two
mutant proteins is in cell viability. Wild-type yeast contain two
RAS genes, RAS1 and RAS2, and require at least one func-
tional RAS gene for mitotic growth (19). As shown in Fig. 3
Upper, rasl RAS2C3l8s spores show normal viability, whereas
rasl ras2C3l9s spores fail to yield colonies. The slightly smaller
spore clones from rasl RAS2C3l8s versus rasi RAS2 strains may
reflect a slight delay in germination of the former cells, since
single rasl RAS2C3l8s cells give rise to the same-sized colonies
as do RAS2 cells on restreaking (Fig. 3 Lower). We conclude
that Ras2p(C318S) supports normal mitotic growth of yeast
and thus fulfills the essential function of yeast Ras in the cell.
In contrast, Ras2p(C319S) does not support mitotic growth
and shows no biological activity by this assay.
The second measure of the biological activity of
Ras2p(C318S) is intragenic suppression of activated alleles of
Table 1. Modification pattern of Ras2 proteins used in this study
Amino acid sequence* Modification
Positions Position Position
Allele 308-317 318 319 Farnesylt Palmitatet
RAS2 SEASKSGSGG C C + +
C318S SEASKSGSGG S C + -
C319S SEASKSGSGG C S - -
A307-317 A C C + +
A307-318 A A C + -
*Alleles were constructed by site-directed mutagenesis.
tRef. 36.
.tRef. 27 and Fig. 1.
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FIG. 1. Palmitate labeling of Ras2 proteins. (Right) Autofluoro-
gram of SDS/PAGE fractionated extracts of strain KP-2 harboring a
YEp51 GAL10-RAS2 plasmid or YEp51 GAL10-RAS2C3lsS plasmid,
prepared after labeling cells in vivo for 2 hr with [3H]palmitate. (Left)
Immunoblot of SDS/PAGE fractionation of the same extracts as in
Right, probed with anti-Ras antibody.
Ras. Strains containing dominant mutations of RAS2, such as
G19V, that lock the protein in its activated state exhibit a
variety of distinct phenotypes. These include diminished ac-
cumulation of glycogen, as monitored by staining colonies with
iodine vapors, and increased sensitivity to heat shock (18, 35).
Second site mutations introduced into the RAS2G19V gene that
diminish the function of the protein attenuate these activated
phenotypes. Thus, the degree to which a mutation inserted into
RAS2G19V gene reverses the activated phenotype of strains
carrying it is a measure of the degree to which that mutation
abolishes the biological activity of the Ras2 protein. As shown
in Fig. 4 Upper, RAS2G19V strains and RAS2G19V,C318S strains
show the same diminished level of iodine strains, compared to
RAS2 strains. In contrast, RAS2G19VC3195 strains show the
same intense level of staining as do ras2 strains. Thus, by this
assay the C318S mutation maintains full biological activity,
whereas the C319S mutation completely abolishes activity. A
similar situation is observed with heat shock: the
RAS2G19V,c318s strain exhibits heat shock sensitivity similar to
that of the RAS2G19V strains, whereas the p4S2G19VC319S
strain behaves like a ras2 strain. In this assay, though, the
RAS2G19V,C318S strain is slightly more resistant than the
RAS2Gl9V strains, suggesting that the C318S mutation is not
completely innocuous. Nonetheless, these results substantiate
the conclusions from the previous assays that the C319S
mutation severely compromises the function of the Ras2
protein whereas the C318S mutation has only a minor effect.
Palmitoylation Is Required for Ras-Mediated Transient
Induction of Intracellular cAMP Levels by Glucose. Whereas
loss of Ras2p palmitoylation has only a minor effect on the
essential functions of Ras2p, strains carrying this mutation are
FIG. 2. Immunofluorescence localization of mutant Ras2 proteins
in yeast. Confocal micrographs of strain Y294 carrying the indicated
RAS2 alleles. Ras proteins were visualized by indirect immunofluo-
rescence using a monoclonal antibody (yRAS2-3G6) raised to yeast
Ras2p.
RAS2
R4S2C318S
FIG. 3. Palmitoylation is not required for Ras-dependent mitotic
growth in yeast. (Upper) Strains Y1808 and Y1810, which are rasl/rasl
RAS2::URA3/RAS2C3l8s and rasl/rasl RAS2::URA3/ras2C3l9s, re-
spectively, were sporulated, dissected on YEPD plates, and grown at
30°C. The four spores from each tetrad are arrayed vertically. As
determined by subsequent tests for uracil auxotrophy, the two smaller
spore clones in each tetrad from strain Y1808 are RAS2C318s and the
two spore clones in each tetrad from strain Y1810 that failed to grow
are ras2C319S. (Lower) The four clones from a single tetrad from strain
Y1808 were restreaked on YEPD and grown at 30°C. The relevant
RAS2 genotype is indicated.
severely compromised for glucose-induced transient activation
of adenylyl cyclase. As has been previously reported and as
shown in Fig. 5, addition of glucose to a rasl RAS2 strain yields
a rapid but transient increase in the intracellular concentration
ofcAMP (20-22, 40). In contrast, addition of glucose to a rasl
RAS2C318S strain yields absolutely no transient increase in
cAMP accumulation. Thus, loss of Ras2p palmitoylation pre-
vents rapid activation of adenylyl cyclase to external stimuli,
presumably as a consequence of diminished membrane local-
ization of Ras2p. However, this deficiency does not yield a
substantive cellular phenotype.
DISCUSSION
Our results have shown that farnesylation of Ras protein, but
not its membrane targeting, is required for Ras to fulfill its
essential function in the cell-that is, regardless of the sub-
cellular location of Ras, productive interaction between Ras
and one or more of the components of the Ras signal trans-
duction pathway is dependent on the farnesyl moiety. In its
essential role in yeast, Ras serves as a substrate for Cdc25p, a
guanine nucleotide exchange factor, and stimulates adenylyl
cyclase, the single essential effector target of Ras in the cell
(18, 24, 41). In vitro analysis suggests that Cdc25p-catalyzed
exchange of guanine nucleotide is not affected by the presence
of the farnesyl residue on Ras (42). However, Kuroda et at (43)
have shown that farnesylated Ras2p had a significantly higher
kinetic affinity for adenylyl cyclase in vitro than did unmodified
Ras2p. Our results are consistent with the hypothesis that the
farnesyl group plays a direct role in the interaction between
Ras2p and adenylyl cyclase and documents that this role of the
farnesyl residue is critical for the biological activity of Ras in
vivo.
We have previously shown that, although a single copy of
ras2C3l9s does not impart essential RAS function to the cell,
rasl ras2 strains carrying multiple copies ofras2C3l9s are viable.
Thus, overexpression of Ras2p(C319S) can compensate for the
reduced activity of the mutant protein. This is consistent with
Proc. Natl. Acad Sci. USA 92 (1995)
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FIG. 4. Intragenic suppression ofRAS2G19v by mutations affecting
post-translational modification. (Upper) RAS2G19v activity as mea-
sured by glycogen accumulation. Isogenic RS62-22A strains contain-
ing the indicated single and double mutations inRAS2 present at single
copy were grown onYEPD plates and treated with iodine vapors. Each
row represents different isolates of the same genotypes. The extent of
staining correlates inversely with the degree of activation of the
RAS/cAMP pathway: strains with low Ras activity stain dark brown,
strains with wild-type activity stain light brown, and strains with high
activity show no staining. (Lower) RAS2Gl9V activity as measured by
heat shock sensitivity. Strains containing the indicated single or double
mutations in RAS2 were incubated on plates at 55°C for the indicated
time and then shifted to 30°C for 24 hr. Strains with high Ras activity
are heat shock sensitive and those with low Ras activity are heat shock
resistant.
the hypothesis that farnesylation of Ras2p facilitates interac-
tion with adenylyl cyclase, since overexpression of a mutant
Ras2p protein with a lowered affinity for its target would be
expected to compensate for the reduced affinity. This was
observed by Kuroda et at (43), who showed that increased
concentrations of nonfarnesylated Ras2p yielded increased
cyclase activity in their in vitro assays.
tim (ninutes)
FIG. 5. Time-dependent in vivo accumulation of cAMP following
glucose addition. Strains Y1808-3A (RAS2) and Y1808-3C
(RAS2C318S) were grown in YEPD to stationary phase and at time 0
glucose was added to 2%. Samples were removed at the indicated times
and the intracellular level ofcAMP was determined as described (40).
Similar results were obtained with strains grown in synthetic medium.
Ras2p that is farnesylated but not palmitoylated, and thus
not targeted to the plasma membrane, promotes cell growth
and, thus by inference, is still capable of stimulating adenylyl
cyclase in vitro. One possible explanation for this result is that
a small fraction of this nonpalmitoylated Ras2p actually resides
in the membrane and provides sufficient stimulation of the
membrane-localized cyclase to yield viable levels of cAMP in
the cell. However, we find that strains containing only one or
two copies of the RA4S2 mutation defective for palmitoylation
exhibit <10% plasma membrane localization as judged by
immunofluorescence. Since other RAS2 mutations with less
severe reductions in biochemical activity show more dramatic
loss of function phenotypes, we do not believe that residual
membrane localization accounts for the wild-type phenotype
of the RAS2C318s mutants. Rather, we suspect that, since
adenylyl cyclase resides in the plasma membrane and cyto-
plasmic compartments in the cell (25, 26), cytoplasmic Ras
protein, as long as it is farnesylated, can activate the cytoplas-
mic adenylyl cyclase.
Ras protein that is farnesylated but delocalized, though
capable of providing sufficient stimulation of adenylyl cyclase
for viability, is not capable of mediating a rapid induction of
cyclase activity in response to stimulation of the cell by glucose.
Thus, membrane targeting is clearly required for Ras to
mediate this signaling event. Restriction of Ras2p to the
plasma membrane may facilitate efficient interaction with
Cdc25p, which is membrane bound and required for transient
activation of cyclase by glucose (M. Jacquet, personal com-
munication; refs. 23 and 44). However, our results indicate that
this signaling pathway is not required for viability in yeast-a
result suggested by previous analysis of rapid exchange mu-
tants of Ras2p (23). Nonetheless, loss of this rapid response
pathway may underlie some of the more subtle phenotypes-
such as delayed germination-ofRAS2C318s strains. By cleanly
separating signaling from viability, these mutant proteins
should help resolve the biological role of this Ras-mediated
signaling pathway.
The results on localization and function of yeast Ras con-
trast with those obtained for mammalian Ras. Buss et at (45)
showed that the farnesyl moiety could be replaced by a
different membrane targeting signal-myristoylation of the
amino terminus-to yield a protein with normal or near-
normal activity. Thus, farnesylation per se is not required for
Ras function in mammalian cells. More recently, Hancock et
at (38) showed that elimination of the palmitoylation site of
Ha-ras or the carboxyl polybasic region of Ki-ras caused loss
of membrane localization. However, in this case the mislocal-
ized protein retained transformation potential and the ability
to mediate activation of mitogen-activated protein kinase, as
long as the Ras protein was farnesylated (39). Thus, the
mammalian Ras protein requires either farnesylation or mem-
brane localization for biological activity.
Alternatively, as we suggest for yeast Ras, farnesylation may
play a critical role in promoting protein-protein interaction of
mammalian Ras, for which some evidence exists (10, 42, 43,
46), but the myristoyl moiety may effectively substitute for
farnesyl in this capacity. If this is the case, then the role of
post-translational modification in Ras-mediated signal trans-
duction may prove to be the same in yeast and mammals.
S.B. and L.C. contributed equally to this work. This work was
supported by National Institutes of Health Grant CA41086 to J.R.B.
1. Buss, J. E. & Sefton, B. M. (1986) Mo. Cell. Biol. 6, 116-122.
2. Clarke, S., Vogel, J. P., Deschenes, R. J. & Stock, J. (1988) Proc.
Natl. Acad. Sci. USA 85, 4643-4647.
3. Gutierrez, L., Magee, A. I., Marshall, C. J. & Hancock, J. F.
(1989) EMBO J. 8, 1093-1098.
RAS2 Allele 40' Heat Shock 20' Heat Shock
RAS2 ='3
Just2G9vcsj95
RAS2GI9V.C31SC
us2GI@.CI9 _E
Cell Biology: Bhattacharya et aL
2988 Cell Biology: Bhattacharya et at
4. Hancock, J. F., Magee, A. I., Childs, J. E. & Marshall, C. J.
(1989) Cell 57, 1167-1177.
5. Casey, P. J., Solski, P. A., Der, C. J. & Buss, J. E. (1989) Proc.
Natl. Acad. Sci. USA 86, 8323-8327.
6. Fujiyama, A. & Tamanoi, F. (1990)1. Biol. Chem. 265, 3362-3368.
7. Clarke, S. (1992) Annu. Rev. Biochem. 61, 355-386.
8. Giannakouros, T. & Magee, A. I. (1992) in Lipid Modifications of
Proteins, ed. Schlesinger, M. J. (CRC, Boca Raton, FL), pp.
135-162.
9. Schafer, W. R. & Rine, J. (1992) Annu. Rev. Genet. 30, 209-237.
10. Marshall, C. J. (1993) Science 259, 1865-1866.
11. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland,
A. M. & Weinberg, R. A. (1993) Nature (London) 363, 45-51.
12. Clark, S. G., Stern, M. J. & Horvitz, H. R. (1992) Nature (Lon-
don) 356, 340-344.
13. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T. & Bow-
tell, D. (1993) Nature (London) 363, 83-85.
14. Li, N., Batzer, A., Daly, R., Yajnik, V., Skolnik, E., Chardin, P.,
Bar-Sagi, D., Margolis, B. & Schlessinger, J. (1993) Nature
(London) 363, 85-88.
15. Stokoe, D., MacDonald, S. G., Cadwallader, K., Symons, M. &
Hancock, J. F. (1994) Science 264, 1463-1467.
16. Leevers, S. J., Paterson, H. F. & Marshall, C. J. (1994) Nature
(London) 369, 411-414.
17. Buday, L. & Downward, J. (1993) Cell 73, 611-620.
18. Toda, T., Uno, I., Ishikawa, T., Powers, S., Kataoka, T., Broek,
D., Cameron, S., Broach, J., Matsumoto, K. & Wigler, M. (1985)
Cell 40, 27-36.
19. Kataoka, T., Powers, S., McGill, C., Fasano, O., Strathern, J.,
Broach, J. & Wigler, M. (1984) Cell 37, 437-445.
20. Purwin, C., Leidig, F. & Holzer, H. (1982) Biochem. Biophys. Res.
Commun. 107, 1482-1489.
21. Mazon, M. J., Gancedo, J. M. & Gancedo, C. (1982) Eur. J.
Biochem. 127, 605-608.
22. Mbonyi, K., Beullens, M., Detremerie, K., Geerts, L. & Thev-
elein, J. M. (1988) Mol. Cell. Biol. 8, 3051-3057.
23. Van Aelst, L., Boy-Marcotte, E., Camonis, J. H., Thevelein, J. M.
& Jacquet, M. (1990) Eur. J. Biochem. 193, 675-680.
24. Jones, S., Vignais, M. L. & Broach, J. R. (1991) Mol. Cell. Biol.
11, 2641-2646.
25. Engelberg, D., Simchen, G. & Levitzki, A. (1990) EMBO J. 9,
641-651.
26. Mitts, M. R., Grant, D. B. & Heideman, W. (1990) Mol. Cell.
Biol. 10, 3873-3883.
27. Deschenes, R. J. & Broach, J. R. (1987) Mol. Cell. Biol. 7,
2344-2351.
28. Rothstein, R. (1991) Methods Enzymol. 194, 281-301.
29. Powers, S., Kataoka, T., Fasano, O., Goldfarb, M., Broach, J. &
Wigler, M. (1984) Cell 36, 607-612.
30. Rose, M. D. & Broach, J. R. (1991) Methods Enzymol. 194,
195-230.
31. Powers, S., Michaelis, S., Broek, D., Santa-Anna, A. S., Field, J.,
Herskowitz, I. & Wigler, M. (1986) Cell 47, 413-422.
32. Furth, M., Davis, L. J., Fleurdelys, B. & Scolnick, E. M. (1982)J.
Virol. 43, 294-304.
33. Rose, M. D., Winston, F. & Hieter, P. (1990) Methods in Yeast
Genetics (Cold Spring Harbor Lab. Press, Plainview, NY).
34. Page, B. D. & Snyder, M. (1992) Genes Dev. 6, 1414-1429.
35. Sass, P., Field, J., Nikawa, J., Toda, T. & Wigler, M. (1986) Proc.
Natl. Acad. Sci. USA 83, 9303-9307.
36. Goodman, L. E., Judd, S. R., Farnsworth, C. C., Powers, S., Gelb,
M. H., Glomset, J. A. & Tamanoi, F. (1990) Proc. Natl. Acad. Sci.
USA 87, 9665-9669.
37. Deschenes, R. J., Stimmel, J. B., Clarke, S., Stock, J. & Broach,
J. R. (1989) J. Biol. Chem. 264, 11865-11873.
38. Hancock, J. F., Paterson, H. & Marshall, C. J. (1990) Cell 63,
133-139.
39. Cadwallader, K. A., Paterson, H., MacDonald, S. G. & Hancock,
J. F. (1994) Mol. Cell. Biol. 14, 4722-4730.
40. Nakafuku, M., Obara, T., Kaibuchi, K., Miyajima, I., Miyajima,
A., Itoh, H., Nakamura, S., Arai, K. I., Matsumoto, K. & Kaziro,
Y. (1988) Proc. Natl. Acad. Sci. USA 85, 1374-1378.
41. Broek, D., Toda, T., Michaeli, T., Levin, L., Birchmeier, C.,
Zoller, M., Powers, S. & Wigler, M. (1987) Cell 48, 789-799.
42. Porfiri, E., Evans, T., Chardin, P. & Hancock, J. F. (1994) J. Biol.
Chem. 269, 22672-22677.
43. Kuroda, Y., Suzuki, N. & Kataoka, T. (1993) Science 259,
683-686.
44. Munder, T. & Kuntzel, H. (1989) FEBS Lett. 242, 341-345.
45. Buss, J. E., Solski, P. A., Schaeffer, J. P., MacDonald, M. J. &
Der, C. J. (1989) Science 243, 1600-1602.
46. Itoh, T., Kaibuchi, K., Masuda, T., Yamamoto, T., Matsuura, Y.,
Maeda, A., Shimizu, K. & Takai, Y. (1993) J. Biol. Chem. 268,
3025-3028.
Proc. Natl. Acad Sci. USA 92 (1995)
